By watching the trading activity of corporate insiders, it will become easier to get a sense of Oragenics, Inc. (NYSE:OGEN)’s prospects. The earliest insider trade took place on 09/18/2018. Koski Family Lp gathered a total of 169.05 thousand shares of company at average share price of $0.42. The total for the purchase was set at $71 thousand. After this transaction, the 10% Owner account balance stood at 147.85 thousand shares. The stock grew 200 percent since that insider purchase. On 06/30/2016, Kirk Randal J, 10% Owner, purchased 226.14 thousand shares at a price per share of $5.2. This added 1.18 million shares to the insider’s fortune and the stock saw a -75.77 percent retreat in value since the news became public. This transaction left 1.55 million shares in the 10% Owner account. On 06/30/2016, 10% Owner Koski Family Lp performed a purchase transaction worth $3.02 million. This purchase at $0.52 each has added 5.82 million shares into the insider’s portfolio position. Meanwhile, shares have recorded 142.31 percent increase since the transaction was reported. The insider now is left with 1.48 million shares remaining in the account. Telling Fred, who performs the Director job, bought 969.18 thousand shares for $503.97 thousand. The acquisition occurred on 06/30/2016 was priced at $0.52 per share. The share price soared 142.31 percent since the reporting date. Telling Fred now left with a stake of 1.32 million OGEN stock worth $1.66 million after the insider buying.
Oragenics, Inc. (OGEN) is expected to jump by 58.73 percent when compared to the closing price of the stock of $1.26 on Thursday, December 06, over the next 12 months, according to price target estimates compiled by finviz.
The shares are currently floating around the first support level of $1.16. Below this, the next support is placed in the zone of $1.06. Till the time, the OGEN stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 57.94 on daily chart, which may remain a cause for concern. If the price breaks below $1.06 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $1.4 mark may result into a pull-back move towards $1.54 level.
OGEN shares dropped -0.1 points or -7.35 percent on Thursday to $1.26 with a light trade volume of 4.478 million shares. After opening the session at $1.27, the shares went as high as $1.44 and as low as $1.2, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $27.72 million and now has 22 million shares outstanding. Oragenics, Inc. (OGEN) stock has gained 14.55 percent of market value in 21 trading days.
OGEN stock has a trailing 3-year beta of 0.91, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$1.45 a share in the trailing twelve months. The stock’s value has fallen -46.36 percent year to date (YTD) against a decline of -65.29 percent in 12 month’s time. The company’s shares still trade -70 percent away from its 1-year high of $4.20 and 231.58 percent up from 52-week low of $0.38. The average consensus rating on the company is 1, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of Oragenics, Inc. (OGEN) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry OGEN operates in has an average P/E of 31.13. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 0 on the Price-to-Sales ratio. Compare this with the industry average P/S of 4. 0 percent is the gross profit margin for Oragenics, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.